Cadent Capital Advisors LLC Buys Shares of 28,268 Hims & Hers Health, Inc. $HIMS

Cadent Capital Advisors LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 28,268 shares of the company’s stock, valued at approximately $1,603,000.

A number of other institutional investors have also modified their holdings of HIMS. Virtus Advisers LLC purchased a new position in shares of Hims & Hers Health during the second quarter valued at approximately $26,000. Quaker Wealth Management LLC purchased a new position in shares of Hims & Hers Health during the 2nd quarter worth $29,000. Bessemer Group Inc. boosted its holdings in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares during the last quarter. Geneos Wealth Management Inc. purchased a new stake in shares of Hims & Hers Health in the first quarter valued at $30,000. Finally, Hilltop National Bank purchased a new stake in shares of Hims & Hers Health in the third quarter valued at $35,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Down 0.8%

Shares of Hims & Hers Health stock opened at $34.54 on Thursday. Hims & Hers Health, Inc. has a twelve month low of $23.97 and a twelve month high of $72.98. The stock has a market cap of $7.86 billion, a price-to-earnings ratio of 63.95, a price-to-earnings-growth ratio of 6.88 and a beta of 2.41. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The company has a fifty day moving average price of $40.50 and a 200 day moving average price of $48.08.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, November 3rd. The company reported $0.06 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The company had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. During the same period last year, the business earned $0.32 earnings per share. The company’s revenue for the quarter was up 49.2% compared to the same quarter last year. Equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health declared that its board has authorized a share repurchase plan on Monday, November 17th that permits the company to repurchase $250.00 million in shares. This repurchase authorization permits the company to purchase up to 3% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s board of directors believes its stock is undervalued.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HIMS. BTIG Research reiterated a “buy” rating and set a $85.00 target price on shares of Hims & Hers Health in a research report on Tuesday, November 4th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $68.00 price target on shares of Hims & Hers Health in a research note on Friday, September 12th. KeyCorp started coverage on shares of Hims & Hers Health in a report on Tuesday, October 21st. They issued a “sector weight” rating on the stock. Wall Street Zen downgraded Hims & Hers Health from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Finally, Barclays assumed coverage on Hims & Hers Health in a research report on Monday, December 8th. They issued an “overweight” rating and a $48.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and a consensus price target of $45.50.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the completion of the sale, the insider owned 6,175 shares of the company’s stock, valued at $226,684.25. This trade represents a 53.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Irene Becklund sold 8,411 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $308,767.81. Following the sale, the insider owned 2,126 shares in the company, valued at $78,045.46. This represents a 79.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 230,835 shares of company stock worth $11,113,714 over the last 90 days. 13.71% of the stock is owned by corporate insiders.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.